Loading…
← CockpitCompetitor Analysis › STTK Shattuck Labs, Inc.Open in the cockpit ↗

Shattuck Labs, Inc.STTKCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 14
Mkt cap
$455M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$5.04M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.1%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$4.47
1D-2.6%
1W-11.5%
1M-23.5%
3M-38.3%
6M-27.6%
YTD+22.5%
1Y+125.8%
ATR %8.7%
Beta1.25
52w lowhigh46.3% off high

What Shattuck Labs does

Employees: 40

Shattuck Labs at a glance

Size Shattuck Labs (STTK) is a United States Health Care company (Biotechnology) with a market value of $455M, the 2747th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.47 on 18 Nov 2026.

Performance Over six months the shares fell 27.6%, against -1.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +4.9%).

Short interest Short interest is 10.6% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 101STTK 73
Six months, rebased to 100: Shattuck Labs against the median of its 20 peers (local-currency closes).

Shattuck Labs financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$1.00M$5.72M$1.66M$652,000
Revenue growth—-83%+245%+154%—
Gross profit-$3.46M-$2.69M$1.89M-$2.38M-$2.72M
EBITDA-$68.6M-$47.8M-$76.5M-$87.9M-$100.0M
Net income-$67.7M-$48.8M-$75.4M-$87.3M-$102M
Free cash flow-$49.8M-$40.0M-$60.6M-$81.6M-$106M
Capital expenditure$191,000$71,000$59,000$407,000$11.6M
Total debt$2.45M$2.42M$3.41M$4.20M$4.90M

Quarterly statements and history in the cockpit →

Shattuck Labs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%041960115180DMACKMDA6589ARVNFENCIRLA0007106037391789NGNEMNPR4147PRTASTTK6-month return →1-month return →
Up and to the right = strong over both horizons. Shattuck Labs is the large dot.

Shattuck Labs competitors and peer comparison

How Shattuck Labs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shattuck Labs against its 20 peers (data as of 18 Nov 2026)
MeasureSTTKPeer medianRank in peer set
1-month return-23.5%-5.4%4th lowest of 21
6-month return-27.6%-1.8%3rd lowest of 19
Distance from 52-week high-46.3%-37.5%7th lowest of 21
Revenue growth (TTM)-100.0%+4.9%2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%

Questions

Which companies are Shattuck Labs's closest peers?
The cockpit's peer set: Komipharm International (041960.KS), Qurient (115180.KS), HanchorBio (7827.TW), DiaMedica Therapeutics (DMAC), Kamada (KMDA), EirGenix (6589.TW), Arvinas (ARVN), TenNor Therapeutics Suzhou (6872.HK).
How has Shattuck Labs stock performed?
Over six months to 18 Nov 2026 the shares returned -27.6% against -1.8% for the median peer; over one year +125.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.